** Shares of Orthocell OCC.AX rise 15.4% to A$1.500, their highest levels since Jan 6
** The regenerative medicine firm says that it plans to enter key markets such as Canada and Thailand, among others, in CY2025
** Orthocell recently submitted its USFDA regulatory application for the clearance to distribute its nerve drug Remplir in the $1.6 bln (A$2.55 bln) U.S. market commercially
** Co expects approval in March/April 2025
** About 3.4 mln shares trade hands, 1.9 times the 30-day average of 1.8 mln
** Stock rose 230.5% in 2024
(1 Australian dollar = $0.6266)
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。